Search Results for “H19-423_V1.0 Latest Test Testking 🍀 H19-423_V1.0 Practical Information 📄 H19-423_V1.0 Test Price 🕔 Go to website ☀ www.pdfvce.com ️☀️ open and search for ➠ H19-423_V1.0 🠰 to download for free 🎤H19-423_V1.0 Download Pdf” – Page 20

Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines

411.

Agache, I.⁺, Song, Y., Posso, M., Alonso-Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C.*, Palomares, O.*, and Jutel, M.*: Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 2021: 76; 45-58. IF: 14.71

o.411

143.	Kulthanan, K., Hunnangkul, S.+, Tuchinda, P., Chularojanamontri, L., Weerasubpong, P., Subchookul, C., and Maurer, M.+: Treatments of cold urticaria: a systematic review. J. Allergy Clin. Immunol. 2019: 143; 1311-1331. IF: 10.23

r.143

27.	Zuberbier, T. and Maurer, M.: EAACI-GA²LEN-EDF-WAO – Guideline on urticaria. In: Akdis, C. A. and Agache, I., editors: Global atlas of allergy. EAACI, 2014

Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence

129.

Maurer, M., Metz, M., Brehler, R., Hillen, U., Jakob, T., Mahler, V., Pföhler, C., Staubach, P., Treudler, R., Wedi, B., and Magerl, M.: Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J. Allergy Clin. Immunol. 2018: 141; 638-649. IF: 14.11

r.129

Adaptation and initial results of the polish version of the GA²LEN chronic urticaria quality of life questionnaire

106

Brzoza, Z.+, Badura-Brzoza, K., Młynek, A., Magerl, M., Baiardini, I., Canonica, G. W., Weller, K., Kocatürk, E., Kalogeromitros, D., Zalewska-Janowska, A., Zuberbier, T., and Maurer, M.: Adaptation and initial results of the polish version of the GA²LEN chronic urticaria quality of life questionnaire (CU-Q2oL). J. Dermatol. Sci. 2011: 62; 36-41. IF: 3.71

123.	Vena, G. A., Maurer, M., Cassano, N., and Zuberbier, T.: Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm. Curr. Opin. Allergy Clin. Immunol. 2017: 17; 278-285. IF: 3.54

r.123

342	Kolkhir, P., Grakhova, M., Bonnekoh, H., Krause, K., and Maurer, M.+**: Treatment of urticarial vasculitis: a systematic review. J. Allergy Clin. Immunol. 2019: 143; 458-466. IF: TBD (IF 2018: 14.11)

280	Asady, A., Ruft, J., Ellrich, A., Hawro, T., Maurer, M.+, and Altrichter, S.: Cholinergic urticaria patients of different age groups have distinct features. Clin. Exp. Allergy 2017: 47; 1609-1614. IF: 5.16

190	Maurer, M.+ Longhurst, H. J., Fabien, V., Li, H. H., and Lumry, W. R.: Treatment of hereditary angioedema with icatibant: Efficacy in clinical trials versus effectiveness in the real-world setting. Allergy Asthma Proc. 2014: 35; 377-381. IF: 3.06

High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study

Siebenhaar, F., Degener, F., Zuberbier, T., Martus, P., and Maurer, M.+: High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J. Allergy Clin. Immunol. 2009: 123; 672-679. IF: 9.16

Results